Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine

Arzneimittel-Forschung/Drug Research

Volumn 49, Issue 4, 1999, Pages 289-296

  Harrer, Gerhart ^a   Schmidt, Ulrich ^b   Kuhn, Ulrike ^b   Biller, Andreas ^c  

^a Inst fur Forensische P der U S   (Austria)

^b AFA Arbeits /F fur A e V   (Germany)

^c Dr Loges + Co GmbH   (Germany)

Author keywords

Antidepressants; CAS 54910 89 3; Depression, mild and moderate episodes; Fluoxetine; LoHyp 57, comparison of equivalence, tolerability; St. John's wort

Indexed keywords

FLUOXETINE; LOHYP 57; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERICUM PERFORATUM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN TOXICITY;

EID: 0032947468     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300417     Document Type: Article

References (20)

1. [1] Vorbach, E. U., Hübner, W. D., Arnold, K. H., Nervenheilkunde 12, 29 (1993)
2. [2] Bergmann, R., Nüßner, J., Demling, J., TW Neurol. Psychiat. 7, 235 (1993)
3. [3] Harrer, G., Schulz, V., Nervenheilkunde 12, 271 (1993)
4. [4] IMS-Health, Global Services, Sonderanalyse, Frankfurt/Main (1997)
5. [5] Felden, K., Arzneimittelprüfrichtlinien, 5. Ergänzungslieferung 1994. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart (1994)
6. [6] Folstein, M. F., Folstein, S. E., Mc Hugh, P. R., J. Psychiatr. Res. 12, 189 (1975)
7. [7] Hamilton, M., Br. J. Soc. Clin. Phys. 6, 278 (1967)
8. [8] Zung, W.W.K., Arch. Gen. Psychiat. 16, 543 (1967)
9. [9] Bullinger, M., Kirchberger, I., von Steinbüchel, N., Z. Med. Psychol. 2, 121 (1993)
10. [10] National Institute of Mental Health, Assessment Manual for Psychopharmacology, Rev. Ed. 217, Bethesda, USA (1976)
11. [11] Linden, M., Vortrag anläßlich der 3. Jahrestagung der Deutschen Gesellschaft für Gerontopsychiatrie und -psychotherapie, Kassel, Februar 1997
12. [12] Linde, K., Ramirez, G., Mulrow, C. D. et al., Br. Med. J. 313, 253 (1996)
13. [13] Volz, H. P., Pharmacopsychiatry 30 (Suppl.), 72 (1997)
14. [14] Harrer, G., Hübner, W. D., Podzuweit, H., J. Geriatr. Psychiatr. and Neurol. 7 (Suppl. 1), 24 (1994)
15. [15] Möller, H. J., Fuger, J., Kasper, S., Pharmacopsychiatry 27, 215 (1994)
16. [16] Volz, H. P., Ärztezeitung 195, 12 (1996)
17. [17] Woelk, H., Burkard, G., Grünwald, J., Nervenheilkunde 12, 308 (1993)
18. [18] Schmidt, U., Nervenheilkunde 10, 10 (1991)
19. [19] Schmidt, U., Fortschr. Med. 111, 279 (1993)
20. [20] Schmidt, U., Harrer, G., Kuhn, U. et al., Nervenheilkunde 12, 314 (1993)